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INTRODUCTION 
Antiretroviral therapy (ART) has led to a significant decline in AIDS - 
associated morbidity and mortality (1). These benefits are in part a result of 
partial recovery of the immune system, manifested by increase in CD4  
T-lymphocytes counts and decrease in plasma HIV-1 viral loads  
(2). In some patients clinical deterioration occurs despite increased CD4 
T-lymphocytes and decreased plasma HIV-1 viral loads  
(3).  This clinical deterioration is due to inflammatory response of the 
immune system to both subclinical pathogens and residual antigens.  
In the mid-1990s, clinicians noticed that certain patients deteriorated after 
starting HAART despite having decreasing HIV-1 RNA levels and rising CD4 
cell counts [2-5]. In these patients, receipt of HAART results in a pathological 
inflammatory response to either previously treated infections or subclinical 
infections [6-8]. This inflammation could result in deleterious clinical outcomes, 
such as culture-negative meningitis or necrotizing lymphadenitis; it has been 
labeled as immune reconstitution disease (IRD) or immune reconstitution 
inflammatory syndrome (IRIS) [9-11]. 
Immune Reconstitution Inflammatory Syndrome (IRIS)  is defined as a 
paradoxical deterioration in clinical status after initiating anti -retroviral therapy 
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attributable to the recovery of the immune response to latent or subclinical 
infection or non-infectious processes. 
Despite numerous descriptions of the manifestations its pathogenesis 
remains speculative. Current theories concerning the pathogenesis of IRIS  
involves a combination of underlying antigenic burden, a degree of immune 
restoration following anti-retroviral therapy and host genetic susceptibility. 
  Immune Reconstitution Inflammatory Syndrome (IRIS) that occurs as a 
result of “unmasking” of clinically silent infection is characterized by atypical 
exuberant inflammation or an accelerated clinical presentation suggesting a 
restoration of antigen-specific immunity.  
Following anti- retroviral therapy an increase in memory CD4 cell types 
is observed (4) possibly as a result of redistribution from peripheral lymphoid 
tissue (5). This CD4 is primed to recognize previous antigenic stimuli and be 
responsible for the manifestations of Immune Reconstitution Inflammatory 
Syndrome (IRIS) seen soon after initiation of Anti Retroviral therapy. 
The best described associations between particular infectious agents and 
IRIS include ophthalmic cytomegalovirus (CMV) disease, disseminated 
infection with Mycobacterium tuberculosis or Mycobacterium avium complex, 
and central nervous system involvement with Cryptococcus neoformans . 
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Risk Factors : 
• Advanced HIV disease -  CD4 counts <50 
• Unrecognized Opportunistic infection or high microbial burden  
• Early initiation of HAART 
• ARV naïve 
• Immune recovery with rapid fall in HIV RNA 
• Genetic factors which can be pathogen specific 
Mycobacteria – TNF-308*2, IL6 – 174*G 
         Herpes virus  - HLA- B44, -A2, -DR2, IL12B3’UTR*1 
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TB- IRIS : 
• Well recognized phenomenon for decades 
• Lymphadenitis (12 – 25 %),  
• 1 – 6 months post initiation of therapy 
• Pulmonary disease, central nervous system-new tuberculomas, fevers, 
ARDS 
• 75% have worsening of original lesions 
• Often required steroids 
• Due to intensification of the cell mediated immune response and 
conversion of TST 
• Concomitant rise in TNF levels 
 
We have very few studies about Immune Reconstitution Inflammatory 
Syndrome and most of it is Western Studies.   
The incidence, risk factors and presentation of IRIS may differ in our 
Indian context.  
As we have very few Indian studies about  IRIS, a study is planned to find 
the clinical spectrum of IRIS in HIV positive patients visiting a tertiary care 
centre at the chennai. 
The present study was undertaken to determine the incidence of IRIS in 
high-risk patients, the risk factors at baseline for developing IRIS, and the long-
term outcome of patients with IRIS.  
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We hypothesized that patients who started HAART in closer proximity to 
the diagnosis of their underlying opportunistic infection and who had a more 
robust response to HAART in terms of  increasing  CD4 levels would be at an 
increased risk for developing IRIS. 
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Aim :                                                    
 To study the profile of Immune Reconstitution Inflammatory Syndrome 
(IRIS) in HIV positive patients on Anti Retroviral therapy (ART) 
Objectives : 
1. Type of Opportunistic Infections 
 2.  Correlation with the CD 4 count 
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REVIEW OF LITERATURE 
Immune Reconstitution Inflammatory Syndrome (IRIS) 
o IRIS can be described as an adverse clinical phenomenon 
following rapid restoration of immune function  in a previously 
severely immune-compromised individual. 
o This is not specific to HIV positive persons on ART but can follow 
recovery from neutropenia (chemotherapy/transplantation) or dose 
reduction/withdrawal of steroids. 
o The syndrome is well-described for  many bacteria, virus, fungi, 
protozoa, helminth, virus related malignancy and non-infectious 
processes. 
o In HIV-infected patients, IRIS can be described as a deterioration 
of the opportunistic infection due to restoration of pathogen 
specific immune responses. 
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FIG 1. PATHOGENESIS AND RISK FACTORS OF IRIS 
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FIG 2. INFECTIOUS AND NON-INFECTIOUS ETILOGY 
OF IRIS 
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DIAGNOSIS OF IRIS : 
In India, the agreed practical definition of IRIS would be the “occurrence 
or manifestations of new opportunistic infections  or existing opportunistic 
infections within six weeks to six months after initiating anti-retroviral 
therapy with an increase in CD4 count” 
‐ Typically, IRIS occurs within 2–12 weeks of the initiation of ART, 
although it may present later (usually between 6 weeks to 6 months) 
‐ The incidence of IRIS is estimated to be 10% among all patients in 
whom ART has been initiated; and up to 25% among those who have 
started ART and who have a CD4 cell count of below 50 cells/mm3 
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FIG 3. CASE DEFINITIONS OF IRIS 
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UNUSUAL PRESENATIONS OF IRIS : 
o Unexpected localized disease, e.g. lymph nodes (appearance or 
enlargement and/or suppuration), or involving liver or spleen 
o Exaggerated inflammatory reaction, e.g. severe fever, with exclusion of 
other causes 
o Painful lesions 
o Atypical inflammatory response in affected tissues, e.g. granulomas, 
suppuration, necrosis 
o Perivascular lymphocytic inflammatory cell infiltrate 
o Progression of organ dysfunction or enlargement of pre-existing lesions 
o Development or enlargement of cerebral space-occupying lesions after 
treatment for cerebral cryptococcosis or toxoplasmosis 
o Progressive pneumonitis or the development of organizing pneumonia 
after treatment for pulmonary MTB or PCP 
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FIG 4. DIAGNOSTIC PROTOCOL FOR IRIS 
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FIG 5. SUMMARY OF INCIDENCE AND RISK FACTORS OF IRIS IN 
PUBLISHED COHORTS 
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FIG 6. DIFFERENTIAL DIAGNOSIS OF IRIS 
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               FIG 7. GENERAL APPROACH TO IRIS 
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              FIG 8. MANAGEMENT OF IRIS 
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Treatment of IRIS : 
o There are no standard guidelines for the treatment of IRIS 
o Milder forms of IRIS resolve with continuing anti-infective therapy and 
anti-retroviral therapy 
o In the majority of cases, ART can be safely continued and need not be 
interrupted 
o In general, most clinicians prefer to continue ART if the CD4 count is 
below 100/mm3 or if the patient presents with IRIS months after the 
initiation of ART 
o However, the discontinuation of ART should be considered if the 
inflammatory responses are considered life-threatening (e.g. intracranial 
IRIS leading to encephalitis, cerebritis, perilesional cerebral oedema and 
pulmonary IRIS with ARDS/acute respiratory distress syndrome), or are 
unresponsive to steroids 
o Discontinuation of the treatment should also be considered if the 
pathogens involved are not amenable to specific antimicrobials (e.g. 
Parvovirus B19, polyomavirus JC causing  progressive multifocal 
leukoencephalopathy), Other Situations when HAART will likely need to 
be discontinued : 
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o  Hepatitis →uncertainty about contribution of drug toxicity 
o Skin eruptions – usually possible to differentiate cutaneous IRIS from 
drug  rash. 
o Non-steroidal anti-inflammatory drugs (NSAIDs) are helpful in 
controlling inflammation and fever associated with IRIS 
o However, in severe IRIS, a short course of oral prednisolone is required 
to alleviate the symptoms 
o The dosage and duration of treatment required is variable and should be 
judged clinically. Severe disease requires at least 1–2 mg of prednisolone 
per kg body weight 
o In a study conduted by Shelburne et all ,To determine whether patients 
with IRIS require more interventions to prevent morbidity and mortality, 
they  collected data regarding invasive procedures and hospitalizations 
during the first year following initiation of HAART as surrogate markers 
for healthcare utilization.  
o In the 12 months after starting HAART, patients with IRIS required  
increased numbers of invasive procedures, such as lumbar punctures to  
relieve increased intracranial pressure, and had a higher number of 
hospitalizations. This implies that, in the short term, these patients require  
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intensification of their healthcare, thereby suggesting that preventive 
strategies might be cost effective. Such strategies might be especially  
effective in developing countries where coinfection with C. neoformans 
or M. tuberculosis is relatively common and the ability to manage  
complex paradoxical reactions readily may be limited [51]. 
Course  of IRIS : 
o Although there may be short-term morbidity associated with IRIS, these 
patients appear to have comparably good long-term outcomes. After 24 
months  of HAART, patients with IRIS were more likely to have  
successful viral suppression and immune reconstitution than patients  
without the syndrome.  In addition, there was no significant mortality  
difference between the two  groups of patients.  In fact, the survival trend  
was in favor of the IRIS patients, which is  likely a reflection of the  
durable viral suppression and immune reconstitution seen in these  
patients. 
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Previous Studies : 
In a study by I. Ratnam, C. Chiu, N.-B. Kandala, and P. J. Easterbrook 
from Department of HIV/Genitourinary Medicine, King’s College London, 
Guy’s, King’s College and St. Thomas’ Hospitals, London, United Kingdom did 
a retrospective study of all patients starting HAART between 1 January 2000 
and 31 August 2002 at a human immunodeficiency virus (HIV) clinic in London 
where a total of 199 patients were included, of whom 50.8% were male, 59.3% 
were black African, 29.1% were white, and 10.5% were black Caribbean. The 
median baseline CD4 cell count and HIV RNA load were 174 cells/L and 37,830 
copies/mL respectively. Forty-four patients (22.7%) experienced an IRIS event 
at a median of 12 weeks after HAART initiation ; 22 events (50%) involved 
genital herpes, 10 (23%) involved genital warts, 4 (9.0%) involved molluscum 
contagiosum, and 4 (9.0%) involved varicella zoster virus infection. Five 
patients had mycobacterial infections, 4 had hepatitis B, 1 had Pneumocystis 
jirovecci infection, and 1 had Kaposi sarcoma. The strongest independent 
predictors of IRIS were younger age at initiation of HAART (Pp.003), baseline 
CD4 cell percentage (odds ratio [OR], 2.97) and ratio of CD4 cell percentage 
to CD8 cell. 
Murdoch and David M did a prospective surveillance cohort and nested 
case-control study in a large university hospital-based antiretroviral therapy 
(ART) clinic where a total of 423 ART-naive HIV-infected South African 
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patients were followed for signs and symptoms IRIS during the first 6 months of 
ART which was published in Journal of International of AIDS Society. During 
the first 6 months of ART, 44 (10.4%) patients experienced IRIS for an overall 
incidence rate of 25.1 cases per 100 patient-years. Diagnoses included 
tuberculosis (18/44, 41%), abscess formation and suppurative folliculitis 
(8/44, 18.2%), varicella zoster (6/44, 13.6%), herpes simplex (4/44, 9.1%), 
cryptococcal meningitis (3/44, 6.8%), molluscum contagiosum (3/44, 6.8%), 
and Kaposi's sarcoma (2/44, 4.5%). Median IRIS onset was 48 days 
(interquartile range, 29-99) from ART initiation. In comparison with controls, 
IRIS cases had significantly lower CD4 cell counts at baseline (79 versus 142 
cells/μl; P= 0.02) and at IRIS diagnosis (183 versus 263 cells/μl; P = 0.05), but 
similar virological and immunological response to ART. In multivariable 
analyses, higher baseline CD4 cell count was protective of developing IRIS (HR 
0.72 per 50 cells/μl increase). Most IRIS cases were mild, with ART 
discontinued in three (6.8%) patients, corticosteroids administered to four (9.1%) 
patients, and hospitalization required in 12 (27.3%) patients. Two deaths were 
attributable to IRIS. 
Weerawat Manosuthi , Sasisopin Kiertiburanakul, Thanongsri Phoorisri, 
Somnuek Sungkanuparph did a retrospective study in Bamrasnaradura Infectious 
Diseases Institute and Ramathibodi Hospital, Thailand were 167 patients with a 
mean age of 34.5 years, median CD4cell counts was 36 cells/mm3 and median 
HIV RNA was 427,000 copies/ml. ART was initiated at a median duration of 2.2 
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months after TB treatment. IRIS was identified in 21 (12.6%) patients. Patients 
with IRIS had a higher proportion of extrapulmonary TB than patients without 
IRIS (P < 0.001). By multivariate analysis, extrapulmonary TB was a risk factor 
for IRIS (odds ratio ¼ 8.225, 95% confidence interval ¼ 1.785e37.911, P ¼ 
0.007). Of 21 patients with IRIS, 15 patients developed IRIS within the first two 
months of ART. The mortality rate in patients with and without IRIS was not 
different. 
Shelburne and  Samuel did a retrospective cohort identified through a 
city-wide prospective surveillance program where a retrospective chart review 
was performed for 180 HIV-infected patients who received HAART and were 
coinfected with Mycobacterium tuberculosis,Mycobacterium avium complex, or 
Cryptococcus neoformans between 1997 and 2000. Medical records were 
reviewed for baseline demographics, receipt and type of HAART, response to 
antiretroviral therapy, development of IRIS, and long-term outcome. In this 
cohort, 31.7% of patients who received HAART developed IRIS. Patients with 
IRIS were more likely to have initiated HAART nearer to the time of 
diagnosis of their opportunistic infection (P < 0.001), to have been 
antiretroviral naive at time of diagnosis of their opportunistic infection (P < 
0.001), and to have a more rapid initial fall in HIV-1 RNA level in response to 
HAART (P < 0.001). 
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 Lawn and Stephen did a retrospective analysis of a study cohort enrolled 
over 3 years within a community-based ART service in South Africa. Patients 
receiving treatment for TB at the time ART was initiated (n = 160) were studied. 
Cases of TB-associated IRD during the first 4 months of ART were ascertained. 
The median baseline CD4 cell count was 68 cells/μl  and ART was initiated after 
a median of 105 days from TB diagnosis. Although IRIS was diagnosed in just 
12% (n = 19) of patients overall, IRIS developed in 32% (n = 12) of those who 
started ART within 2 months of TB diagnosis. Pulmonary involvement was 
observed in 84% (n = 16) and intra-abdominal manifestations were also 
common (37%). Overall, 4% (n = 7) of the cohort required secondary level 
health-care for IRIS and two (1%) patients died. In multivariate analysis, risk of 
IRIS was strongly associated with early ART initiation and low baseline CD4 
cell count. Of patients with CD4 counts < 50 cells/μl, the proportions who 
developed IRD following initiation of ART within 0-30, 31-60, 61-90, 91-120 
and > 120 days of TB diagnosis were 100%, 33%, 14%, 7% and 0%, 
respectively. 
Manabe, Yukari C, Campbell, James D, Sydnor, Emily, Moor  and 
Richard D did a study which was published in Journal of Acquired Immune 
Deficiency Syndromes Dec 2001.  Here patients from the Johns Hopkins HIV 
Clinic who had IRIS were identified and matched with 4 controls without IRIS 
who had initiated HAART within 6 months of the case. Forty-nine cases of IRIS 
were identified.  Patients presented a median of 29 days from the initiation of 
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HAART (range: 4 to 186 days). A multivariate analysis showed that the 
development of IRIS was independently associated with using a boosted 
protease inhibitor (BPI) (odds ratio [OR] = 7.41; P = 0.006), a nadir CD4 
count <100 cells/mm3 (OR = 6.2; P < 0.001), and a plasma HIV viral RNA 
decrease of more than 2.5 log at the time of IRIS compared with RNA levels 
before the initiation of HAART. Incrementally greater decreases in viral loads 
directly correlated with increased risk for the development of IRIS. 
TB – IRIS : 
• Paradoxical reactions have been seen in TB prior to HIV  thus IRIS 
phenomena in coinfected pts may have been under reported 
• 29 - 36 % coinfected pts on TB Rx and HAART develop clinically 
apparent  IRIS  
• Radiologic deterioration in 46% 
• More frequent in HIV+ than HIV – patients 
• 36% (12/33) Narita M, et al. AJRCCM 1998;158:157. 
• 32% (6/19)   Navas E, et al. ICAAC, 1999. 
• 6%   (6/82)   Wendel K, et al Chest  2001;120:193. 
• 30.2% (26/86) Shelburne S, et al AIDS 2005; 19:399 
• Associated with restoration of TST reactivity 
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• Majority of cases of IRIS occurred in pts who were being treated for 
TB when HAART initiated 
• Duration of TB Rx  median = 2 months prior to IRIS presentation 
• Duration of HAART median  = 1month prior to IRIS presentation 
• 50% with undetectable HIV RNA at time of IRIS 
• Median CD4#  205 from nadir of 51 ( 26 – 103 ) 
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MATERIALS AND METHODOLODY 
This study is a case control study done on HIV positive patients on 
Antiretroviral Therapy at Government General  Hospital at Chennai.  
Immune Reconstitution Inflammatory Syndrome (IRIS) cases were 
diagnosed according to the latest NACO guidelines. 
The cases included HIV positive patients who developed Immune 
Reconstitution Inflammatory Syndrome (IRIS) during Antiretroviral therapy 
(ART) and the controls included patients who did not develop IRIS during the 
ART. 
Inclusion Criteria :  
1). HIV positive patients on Anti Retroviral therapy of age > 18yrs with 
an increase in CD4 count 
2). Occurrence of  opportunistic infection (New OI) or worsening of 
symptoms (Existing OI) within 6 weeks to 6 months after initiation of 
Antiretroviral therapy 
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Exclusion Criteria :  
1). Patient not on Anti Retroviral Therapy 
2). Poor adherence 
3). Defaulters 
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RESULTS AND ANALYSIS 
This was a case control study where 50 IRIS cases were diagnosed in 
HIV positive patients on Antiretroviral therapy based on the NACO guidelines 
both retrospectively and prospectively which occurred between May 2008 to 
May 2010 and compared with 80 controls who were HIV positive patients on 
Antiretroviral therapy but did not develop IRIS. 
The cases and controls were compared based on Age, Sex, Initial         
CD4 count, Final CD4 count, CD4 rise, Duration of ART, Type of ART and 
then the opportunistic infections  and their relation to CD4 count was analysed. 
 
 
 
 
 
 
 
  
 
33 
 
 
      
 
 
 
 
 
 
 
CHART 1 : AGE DISTRIBUTION 
• The mean age of the cases is 36 
• The mean age of the controls is 37 
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CHART 2 :   SEX DISTRIBUTION 
• In cases, 76% are  males and 24% are females 
• In controls, 65% are males and 35%  are females
7 
24
6 
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CHART 3 : CD4 DISTRIBUTION 
In cases,    the mean initial CD4 count is 135 
          the mean final CD4 count is 239 
           the mean CD4 count rise is 115 
In controls,   the mean initial CD4 count is 116 
             the mean final CD4 count is 222 
             the mean CD4 count rise is 103 
115
115
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CHART 4 :   MEAN DURATION OF ART 
In cases the mean duration of ART was 4 months 
In controls the mean duration of ART was 4.5 months 
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CHART 5 : TYPE OF ART 
In cases  -     64% were on L+S+N regimen 
  24% were on Z+L+N regimen 
  8% were on L+S+E regimen  
4% were on Z+L+E regimen 
   In controls -  54% were on L+S+N regimen 
      46% were on Z+L+N regimen 
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CHART 6 : TYPE OF OPPORTUNISTIC INFECTION IN THE 
DIAGNOSED IRIS PATIENTS 
22% with Pulmonary tuberculosis 
18 with Tuberculous lymphadenitis 
16% with  Pnuemocystis Jiroveci Pnuemonia 
10% with Cryptococcal Meningitis 
10% with Herpes Zoster 
8% with Disseminated Tuberculosis 
6% with Tuberculous Meningitis 
2%  with Cytomegalovirus retinitis, 2% with Oesophageal candidiasis,  2% with 
Aspergilloma, 2% with Non Hodgkins Lymphoma and2% with Acute 
Transverse Myelitis  
0 5 10 15 20 25
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TUBERCULOUS LYMPHADENITIS
DISSEMINATED TUBERCULOSIS
TUBERCULOUS MENINGITIS
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CHART  7 : TB IRIS AND OTHER OPPORTUNISTIC INFECTIONS 
• 54% of the diagnosed IRIS patients had tuberculosis 
• 46% constituted rest of all the opportunistic infections     
     
54
46
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CHART 8 : SUBTYPES OF TB IRIS 
• 41% with Pulmonary tuberculosis 
• 33% with Tuberculous lymphadenitis 
• 15% with Disseminated tuberculosis 
• 11% with Tuberculous meningitis
43
33
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CHART 9 : MEAN DURATION BETWEEN ATT AND ART OF 
TB IRIS PATIENTS 
• The mean duration between ATT and ART of TB IRIS patients is 2.5 
months
0
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DURATION  
OF ART IN  
MONTHS 
 
 
INITIAL CD4 COUNT 
CHART 10 : CORRELATION BETWEEN INITIAL                 
CD4 COUNT AND THE DEVELOPMENT OF IRIS 
• There is a weak correlation between the initial CD4 count and the 
development of IRIS 
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CD4 COUNT RISE 
CHART 11 : CORRELATION BETWEEN THE CD4 COUNT 
RISE AND DEVELOPMENT OF IRIS 
• There is a weak correlation between the CD4 count rise and the 
development of IRIS 
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RESULTS : 
o The mean age of the IRIS  patients was 36yrs. 
o 76% of the patients were of male sex and the rest 24% were of 
female sex. 
o The mean initial CD4 count was 135. 
o The mean final CD4 count was 239. 
o The mean CD4 count rise was 115. 
o The mean duration of ART  in IRIS patients was 4 months. 
o 64% of the IRIS patients were on Lamivudine + Stavudine + 
Nevirapine Regimen, 24% of them on Zidovudine + Lamivudine 
+Nevirapine regimen,  8% were on Lamivudine + Stavudine + 
Efavirenz  and 4% were on Zidovudine + Lamivudine + Efavirenz. 
o The most common opportunistic infection was the Pulmonary 
Tuberculosis, secondly  Tuberculous Lymphadenitis and thirdly 
Pneumocysitis Jiroveci Pneumonia. 
o 54% of the IRIS patients had Tuberculosis. 
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o Among Tuberculosis patients 41% of the patients had Pulmonary 
Tuberculosis, 33% of the patients had Tuberculous 
Lymphadenitis, 15% had Disseminated Tuberculosis and 11% had 
Tuberculous Meningitis. 
o In TB IRIS patients the mean duration between ATT initiation and 
ART initiation was 2.5 months. 
o There is a weak correlation between initial CD4 count and the 
development of IRIS. 
o There is a weak correlation between CD4 count rise and the 
development of IRIS. 
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DISCUSSION : 
 In this study a total of 50 cases of HIV postive patients on ART who 
developed IRIS were identified and were matched with 80 controls of HIV 
patients on ART who did not develop IRIS . 
 Following matching which was done for Age, Sex, CD4 count and Type 
of ART the opportunistic infections  and their relationship to CD4 count was 
analysed. 
             
o In this study the most common opportunistic infection was 
Mycobacterium Tuberculosis followed by Pnuemocystis 
infection.  This is in accordance with the study by Narita M (8) 
where Mycobacterium Tuberculosis is the most common 
opportunistic infection in IRIS. 
o In Tuberculosis, Pulmonary tuberculosis was the  most common 
opportunistic infection, secondly Tuberculous lymphadenitis 
followed by Disseminated Tuberculosis. This is in accordance 
with the study done by Lawn SD (9) where pulmonary tuberculosis 
was the most common  type of TB IRIS. 
o In our study, patients diagnosed with IRIS initiated HAART in 
closer   proximity to the diagnosis of their opportunistic infection 
  
 
47 
 
compared with patients who did not develop IRIS. This is 
consistent with a previous report of 17 HAART-treated patients 
coinfected with M. tuberculosis and HIV [10]   
o Biological reasons for this association are unclear at present, 
although we speculate that patients who receive prolonged therapy 
for their opportunistic infection prior to starting HAART will have 
decreased microbial antigen burdens when HAART is initiated. 
This, in turn, would provide less material to stimulate a 
reconstituting immune system once HAART is begun. These 
concerns may lend added support to the recent recommendations 
to consider delaying HAART for 4-8 weeks after starting M. 
tuberculosis therapy in coinfected patients [42]. 
o TB IRIS occurred most commonly 2.5 months after initiating 
ART.  
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o There was weak correlation between a lower CD4 count or higher 
CD4 rise and the incidence of IRIS. This result was  in accordance 
from  the study by Shelburne, Samuel A(51) where a significant 
association between CD4 cell count rise and the diagnosis of IRIS 
was not seen until later in therapy . 
o It has been noted that reductions in HIV-1 RNA levels in response 
to HAART result initially in redistribution of memory CD4 
lymphocytes  
o This redistribution of activated CD4 lymphocytes may be,atleast 
partly responsible for the manifestations of IRIS, which could 
explain why the rise in CD4 cell count appears delayed compared 
with the viral load decrease  
o  This result was not in accordance from  the study by Lenzo N (11) 
where there was a strong association between a lower CD4 count 
the development of IRIS. 
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CONCLUSION: 
o In our study the  most common opportunistic infection in Immune 
Reconstitution Inflammatory Syndrome  in HIV positive patients 
on Antiretroviral therapy is Mycobacterium Tuberculosis 
followed by Pnuemocystis infection. 
o In Tuberculosis, Pulmonary Tuberculosis was the most common 
opportunistic infection followed by Tuberculous lymbphadenitis. 
o Here, TB IRIS most commonly occurred 2.5 months after 
initiating of anti retroviral therapy. 
o There is a weak correlation between the a lower CD4 count and 
the development of IRIS. 
o There is a weak correlation between the CD4 rise and the 
development of IRIS. Hence it is vital to include HIV-1 RNA load 
measurement  to diagnose IRIS. 
o IRIS is a syndrome that occurs because a patient develops an 
exuberant response to appropriate therapy.  
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o The inclusion of IRIS in the differential diagnosis of a patient who  
presents with an inflammatory process after initiating HAART  
allows for a focused approach to diagnosis and therapy.  
o These patients often require significant interventions to minimize  
short-term morbidity but their long-term outcome appears  
relatively good.  
o Further studies looking at how to decrease the rate of IRIS in high-
risk patients appear warranted by its prevalent nature and the 
association of IRIS with increased hospitalizations and invasive 
procedures. 
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LIMITATIONS : 
o This is a small scale study where only 50 diagnosed cases of IRIS 
are analysed.  
o The diagnosis of IRIS was based on only the rise in CD4 count and 
did not include a fall in HIV RNA levels. 
o Drug Resistance to antiretroviral therapy was not ruled out.  
o Drug Resistance opportunistic infection was not ruled out. 
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RECOMMENDATIONS : 
o A large scale randomised controlled study is recommended. 
o Diagnosis of IRIS should include a fall in the HIV RNA levels and a 
rise in CD4 count. 
o Resistance testing to antiretroviral therapy should be done before a 
case is diagnosed as IRIS. 
o Drug resistant opportunistic infection should be ruled out before 
diagnosing IRIS. 
o Studies  of  early  vs.  deferred  HAART  in  TB  patients  may  provide 
valuable information on the optimal timing of HAART. 
o Initiate HAART before CD4 drops verylow. 
o Exclude OI before starting HAART. 
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Proforma  :   
              1). Serial No:  
              2).I.P No : 
              3). Name:  
              4). Age: 
              5). Sex: 
              6). Occupation: 
              7). Place: 
              8). Duration of HIV +ve status: 
              9). Duration of ART: 
             10). Drugs : 
Risk factors:  Yes  No 
Male sex     
Younger age     
ART within 6 weeks     
Low baseline CD4 count at ART initiation     
Low CD4 cell percentage at ART initiation     
Lower CD4:CD8 ratio at ART initiation     
Prompt rise of CD4 count     
High bacillary burden     
Started on Protease Inhibitor (PI)     
Disseminated TB/ Extrapulm TB/Advanced TB     
 
  
 
63 
 
CLINICAL FEATURES : 
       Fever : 
       Lymhadenopathy : 
      Skin lesions : 
      Cough : 
      Expectoration: 
      Hemoptysis : 
       Dyspnoea : 
      Chest pain:   
      Palpitation: 
      Pedal edema: 
      Abdominal distension: 
      Loose stools :  
      Urine output     adequate /decreased 
      Headache : 
     Neck pain : 
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     Neck Stiffness: 
     Vomiting : 
    Altered sensorium  :  
    Seizures : 
   Focal Deficits :  
 PERSONAL HISTORY: 
     Smoker     yes/no            alcohol        yes/no 
     DM            yes/no             SHT             yes/no      
CLINICAL FINDINGS: 
      Pallor: 
      Ictreus : 
      Pedal edema: 
     Lymphnodes : 
      JVP 
      Pulse 
      BP 
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    BMI 
    CVS 
    RS 
INVESTIGATIONS: 
    Blood sugar 
    Urea 
    creatine 
    LFT 
    CHG 
   T.Chol 
    LDL 
    TGL 
    HDL 
    ECG 
   ECHO   
Chest X ray : 
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CT chest : 
Sputum AFB x 2 : 
Sputum C/S : 
 
 
 
 
Others : 
 
 
 
 
 
 
 
CD 4 count  (Initial)  
CD  4 count  (Final)  
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Clinical Spectrum : 
1). Mycobacterium Tuberculosis   
2). Pneumocystis Carinii Pneumonia    
3). Cryptococcous   
4). Toxoplasmosis   
5). Cytomegalovirus   
6). Herpes  Virus (Herpes Zoster and Herpes Simplex)   
7). Cryptospora and Isospora   
8). Hepatits B virus or Hepatits C Virus   
9). Progressive multifocal leucoencephelitis   
10). Molluscum contagiosum and genital warts   
11). Rheumatoid arthritis   
12). Systemic Lupus Erythematosus   
 
 TREATMENT DETAILS :  
 
  OUTCOME: 
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ANNEXURE 2 : Masterchart  Cases (50) 
SR. 
NO 
NAME  AGE  SEX 
INITIAL 
CD4 
FINAL 
CD4 
CD 4 RISE 
TYPE OF 
ART 
DURATION 
OF ART 
(months) 
OPPORTUNISTIC 
INFECTION 
Duration if on 
ATT (months) 
1. 
Kumaran   38  M  105  193  88 
L+ S+ N 
6 
Pulmonary 
Tuberculosis  3 
2. Selvi   43  F  150  201  51  Z+ L+ N  5  Pulmonary 
Tuberculosis  1 
3. Babu   41  M  95  118  123  L+ S+  N  6  Pulmonary 
Tuberculosis  2 
4. Geetha  33  F  248  307  59  L+ S+  N  5  Pulmonary 
Tuberculosis  4 
5. Jagadesh  34  M  160  180  120  L+ S+ N  2  Pulmonary  
Tuberculosis  3 
6. Sheela   29  F  256  454  248  L+ S+ N  8  Pulmonary 
Tuberculosis  3 
7. Ganesh  35  M  42  145  103  Z+ L+ N  2  Pulmonary 
Tuberculosis 
8. Ayesha  31  F  139  330  191  Z+ L+ N  2  Pulmonary  
Tuberculosis 
9. Gopal  52  M  186  255  69  L+ S+  N  4  Pulmonary 
Tuberculosis  2 
10. Mohan  30  M  128  207  79  L+ S+ N  3  Pulmonary 
Tuberculosis  2 
11. Sampath  42  M  242  374  132   Z+ L+ N  4  Pulmonary 
Tuberculosis  3 
12. Vasantha  48  F  204  252  78  L+ S+ N  6  Tuberculous 
lymphadenitis  4 
13. Ashok  35  M  107  177  70  Z + L + N  4  Tuberculous 
lymphadenitis 
14. Asraf  28  M  124  225  101  L + S + E  6  Tuberculous 
lymphadenitis  2 
15. Selva   37  M  211  272  61  L+ S+ N  5  Tuberculous 
lymphadenitis 
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16. Ravi   44  M  102  250  148  L+ S + E  2  Tuberculous lymphadenitis  1 
17. Renuka  25  F  182  275  93  Z+ L+ N  6  Tuberculous lymphadenitis   
18. Ganamurthy  42  M  122  304  182  L+ S+ N  2  Tuberculous lymphadenitis 
19. Manohar  27  M  60  188  128  L+ S +N  2  Tuberculous lymphadenitis   
20. Naveenbabu  45  M  102  202  100  L+ S+ N  6  Tuberculous lymphadenitis  1 
21. Gajendiran   33  M  27  136  109  Z+ L+ N  4  Disseminated Tuberculous  3 
22. Yasim   28  M  101  220  119  L+ S+ N  3  Disseminated Tuberculosis  2 
23. Seetha  42  F  370  537  167  L+ S+ E  5  Disseminated Tuberculosis  2 
24. Ganesan  40  M  210  315  105  L+ S N  5  Disseminated Tuberculosis  4 
25. Partheeban  41  M  97  214  117  Z+ L+ E  4  Tuberculous Meningitis 
26. Vinoth  32  M  82  193  111  Z+ L+ N  7  Tuberculous Meningitis 
3 
27. Pravin   34  M  40  150  90  L+ S+ N  2  Tuberculous Meningitis 
28. Jagadesh  34  M  192  264  72  L+ S+ N  6  PCP Pneumonia 
29. Ashiya  28  F  32  261  229  L+ S+ N  2  PCP Pneumonia 
30. RamaKrishna  30  M  86  154  68  L+ S+ N  6  PCP Pneumonia 
31. Narayanan  39  M  300  370  270  Z+ L+ N  2  PCP Pneumonia 
32. Padmavathy  32  F  90  176  86  Z+ L+ N  3  PCP Pneumonia 
33. 
janardhanan 
39  M  100  172  72 
L+ S+ N 
2  PCP Pneumonia 
34. Aranya  34  F  160  294  134  L+ S+ E  5  PCP Pneumonia 
 
35. Raman  38  M  145  250  105  L+ S+ N  4  PCP Pneumonia 
 
36. Abdul 
Khader 
39  M  71  276  205  Z+ L+ N  3  Cryptococcal Meningitis 
37. Harish  45  M  102  205  103  L+ S+ N  3  Cryptococcal Meningitis 
38. Asif  31  M  34  144  110  L+ S+ N  2  Cryptococcal Meningitis 
39. Surendaran  38  M  95  308  213  L+ S+ N  4  Cryptococcal Meningitis 
40. Jebastian  47  M  150  216  66  L+ S+ N  5  Crytococcal Meningitis 
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41. Ashok  37  M  177  265  88  L+ S+ N  2  Non Hogkins Lymphoma 
42. Prema  33  f  125  199  74  L+ S+ N  2  Herpes Zoster 
43. Suresh 
Kumar 
36  M  101  153  52  L+ S+ N  5  Herpes Zoster 
44. Salim  27  M  108  240  132  L+ S+ N  4  Herpes Zoster 
45. Abdul   31  M  145  268  123  Z+ l+ N  3  Herpes Zoster 
46. Sarumathi  25  F  49  133  84  Z+ L+ E  8  Herpes Zoster 
47. Ismail  45  M  112  132  120  L+ S+ N  6  CMV Retinitis 
48. Satish  49  M  96  256  160  L+ S+ N  7  Aspergilloma 
49. Sethu  34  M  258  310  52  L+ S+ N  1.5  Acute Transverse myelitis 
50. Peter  34  M  130  230  100  L+ S+ N  2  Oesophageal Candidiasis 
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ANNEXURE 3 – Masterchart Controls  ( 80) 
 
SR.NO 
NAME AGE SEX INITIAL CD 4 FINAL CD 4 CD 4 RISE REGIMEN DURATION OF 
ART (months) 
1. abdulla 50 M 164 268 104 3 6 
2. venkatesh 40 M 189 298 193 3 9 
3. mallika 30 F 139 332 119 3 9 
4. devaki 30 F 103 279 76 3 3 
5. sukanya 35 F 67 189 122 1 3 
6. wilfred 35 M 87 171 84 3 3 
7. janardhan 32 M 107 209 102 3 3 
8. chandra 47 F 139 225 86 3 9 
9. susheela 47 F 160 225 65 3 3 
10. Kumari 46 F 50 170 120 3 3 
11. rajkumar 53 M 144 212 68 3 3 
12. Mani  54 M 181 279 98 3 5 
13. Ashok 53 M 152 283 131 3 6 
14. manohar 38 M 128 225 61 3 9 
15. Harish  40 M 11 138 127 3 6 
16. Anandan  38 M 153 369 216 3 6 
17. Jagadish 33 M 90 160 70 3 6 
18. Santhosh 37 M 139 220 81 3 6 
19. George 53 M 142 212 68 3 9 
20. Vasanthi 38 F 75 280 205 3 6 
21. Janardan 36 M 126 235 99 3 3 
22. Susheela 32 F 124 176 52 3 5 
23. Jayaram 43 M 169 385 216 3 3 
24. Bhaskar 38 M 180 329 149 3 6 
25. Prema kumari 36 F 70 181 111 3 3 
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26. Chandravathi 30 F 165 323 158 3 6 
27. Anandkumar  42 M 57 108 51 3 3 
28. Jagannath 38 M 18 83 65 3 6 
29. Balraj 34 M 175 262 87 3 6 
30. Lakshmi 34 F 186 291 105 3 3 
31. Sarojini 35 F 167 259 92 3 3 
32. Venkatraman 47 M 64 180 116 3 3 
33. Ganga 65 F 76 158 82 1 3 
34. Shobana  36 F 169 228 59 1 9 
35. Venkatesan  38 M 70 198 128 1 3 
36. Salima  35 F 175 256 81 1 9 
37. Narayanan 46 M 175 258 83 3 3 
38. Ashok 30 M 71 138 67 3 3 
39. Bashir 39 M 65 280 215 1 3 
40. Mohammed 55 M 180 250 70 1 3 
41. Palani 49 m 176 292 116 1 3 
42. Ameer 46 m 193 249 56 3 6 
43. Divya 58 f 114 178 64 3 3 
44. Sita 66 f 168 238 70 3 3 
45. Vimala 32 F 133 245 112 1 2 
46. Karthick 44 M 89 254 165 1 2 
47. Pari  38 M 120 222 102 1 3 
48. Narayanan 39 M 79 189 110 1 3 
49. Vinoth  27 M 144 235 91 1 4 
50. Kavitha 45 F 65 189 124 1 1 
51. Vincent 46 M 122 189 67 1 3 
52. Abdulla 36 M 113 189 73 1 8 
53. Sukumar  37 M 90 176 86 1 3 
54. Hemanth 50 M 88 183 95 1 3 
55. Ayesha 33 F 112 234 122 1 4 
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Regimens :  1- Lamivudine + Stavudine + Nevirapine 
  2 – Zidovudine + Lamivudine + Nevirapine 
  3 – Lamivudine + Stavudine + Efavirenz 
4 – Zidovudine + Lamivudine + Efavirenz
56. Abdul Rahman 41 M 47 157 110 1 2 
57. Rakesh 36 M 160 220 60 1 5 
58. Partheeban 43 M 100 198 98 1 3 
59. Moorthy 39 M 59 178 119 1 7 
60. Jagadesh 39 M 97 178 81 1 4 
61. Ashiya 33 F 89 190 101 1 6 
62. RamaKrishnan 29 M 80 279 199 1 3 
63. Narayanan 34 M 130 278 148 1 2 
64. Padmavathy 43 F 120 220 100 1 4 
65. Janardhanan 42 M 118 201 83 1 3 
66. Abdul Khader 40 M 47 150 103 1 5 
67. Harish 33 M 89 210 121 1 6 
68. Asif ali 38 M 79 130 51 1 3 
69. Surendaran 35 M 101 220 119 1 4 
70. Parvathy 40 F 90 173 83 1 5 
71. Dinesh 33 M 87 186 99 3 7 
72. George 38 M 69 130 61 1 2 
73. Harikumar 46 M 220 301 81 1 5 
74. Lavanya  27 F 145 237 92 1 6 
75. Manohar 37 M 92 176 84 1 3 
76. Padmini 39 F 90 145 55 1 4 
77. Ramanathan 33 M 110 230 120 1 4 
78. Sathyanarayana 42 M 167 234 67 1 6 
79. Rohini 39 F 88 277 129 1 4 
80. Pushpa 32 F 134 236 102 3 5 
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   ABBREVATIONS 
IRSIS :  Immune Reconstitution Inflammatory 
              Syndrome 
ART :    Anti Retroviral therapy 
CRP :    C‐Reactive Protein  
CMV :   Cytomegalovirus  
HSV :   Herpes Simplex Virus  
MAC :   Mycobacterium avium complex 
LDH :    Lactate dehydrogenase  
PCP:     Pneumocystis Carinii Pneumonia 
PCR :    Polymerase Chain Reaction  
 
 
   
PATIENT CONSENT FORM 
Study detail. 
Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV +ve patients on  Anti Retroviral 
therapy (ART) 
 
Study centre  :Institute of internal medicine / Madras Medical College- ART centre 
Patients Name  : 
Patients Age  : 
Identification number : 
      Patient may check (     ) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I have the opportunity to ask question 
and all my questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to withdraw at any time without giving 
reason, without my legal rights being affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethics committee and the 
regulatory authorities will not need my permission to look at my health records both in respect of current study and 
any further research that may be conduction in relation to it,even I withdraw from the study I agree to this 
access.However, I understand that my identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of any data or results that arise from this 
study. 
I agree to take part in the above study and to comply with the instructions given during the study and faithfully 
cooperate with the study team and to immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. 
I hereby consent to participate in  this study. 
I hereby give permission to undergo complete clinical examination and diagnostic tests including hematological 
.biochemical, radiological tests. 
Signature/thumb impression:    place   date 
Patients Name and Address: 
 
Signature of investigator :   place   date 
Study investigator’s Name : 
 
